CBD helps reduce lung damage from COVID by increasing levels of protective peptide One way CBD appears to reduce the “cytokine storm” that damages the lungs and kills many patients with COVID-19 Effects of cannabis on lung function: a population-based cohort study The effects of cannabis on lung function remain unclear and may be different from those of tobacco. We compared the
CBD helps reduce lung damage from COVID by increasing levels of protective peptide
One way CBD appears to reduce the “cytokine storm” that damages the lungs and kills many patients with COVID-19 is by enabling an increase in levels of a natural peptide called apelin, which is known to reduce inflammation and whose levels are dramatically reduced in the face of this storm.
Dental College of Georgia and Medical College of Georgia researchers reported this summer CBD’s ability to improve oxygen levels and reduce inflammation as well as physical lung damage in their laboratory model of deadly adult respiratory distress syndrome, or ARDS.
Now they have shown that apelin levels go way down with the viral infection, which has killed 1 million people worldwide, and that CBD quickly helps normalize those levels along with lung function.
“It was dramatic in both directions,” says Dr. Babak Baban, DCG immunologist and associate dean for research, of shifting apelin levels in both circulating blood and lung tissue.
Blood levels of the peptide dropped close to zero in their ARDS model and increased 20 times with CBD, they report in the Journal of Cellular and Molecular Medicine.
“CBD almost brought it back to a normal level,” Dr. Jack Yu, physician scientist and chief of pediatric plastic surgery at MCG, says of the apparent first connection between CBD and apelin.
Apelin is a pervasive peptide made by cells in the heart, lung, brain, fat tissue and blood, and is an important regulator in bringing both blood pressure and inflammation down, says Baban, the study’s corresponding author.
When our blood pressure gets high, for example, apelin levels should go up in the right place, like endothelial cells that line blood vessels, to help bring it down. Apelin should do the same to help normalize the significant increases in inflammation in the lungs and related breathing difficulties associated with ARDS.
“Ideally with ARDS it would increase in areas of the lungs where it’s needed to improve blood and oxygen flow to compensate and to protect,” Baban says. But when they looked at their ARDS model, apelin didn’t do either, and instead decreased in both the lung tissue itself and the general circulation. Until they gave CBD.
They reported this summer in the journal Cannabis and Cannabinoid Research that treatment with CBD reduced excessive lung inflammation, enabling improvements in lung function, heathier oxygen levels, and repair of some of the structural damage to the lungs that are classic with ARDS. The investigators said then more work was needed, including finding how CBD produced the significant changes as well as human trials, before it should be included as part of a treatment regimen for COVID-19.
Now they have correlated those improvements with regulation of apelin. While they don’t attribute all CBD’s benefits to apelin, they say the peptide clearly has an important role in this scenario. They also don’t yet know whether the novel coronavirus, or CBD for that matter, have a direct effect on apelin, or if these are downstream consequences, but they are already pursuing answers to those unknowns.
“It is an association; we don’t know yet about causative, but it is a very good indicator of the disease,” Baban says of the bottom line impact of the viral infection on apelin levels.
The now familiar spiked virus enters human cells via the also pervasive angiotensin-converting enzyme 2, or ACE2, receptor. ”The spike proteins have just the right docking mechanism,” says coauthor Yu. And there is plenty of common ground between ACE2 and apelin, including the fact that many cell types and tissues have both, including the lungs.
Apelin and ACE2 also normally work together to control blood pressure, and upregulation of both may be helpful in cardiovascular disease, including heart failure, by decreasing blood pressure while increasing the heart’s ability to pump. In fact, apelin and ACE2 work together to regulate a healthy cardiovascular system and they are factors in pretty much any condition, like obesity or hypertension, that hurt the cardiovascular system, Baban says.
Like other disease, the novel coronavirus appears to upset their positive partnership. The virus’ binding to the receptor for ACE2 has been shown to decrease ACE2 levels and increase levels of the powerful blood vessel constrictor angiotensin II, because less angiotensin II gets degraded and fewer vasodilators get produced, which worsens the patient’s prognosis.
“Instead of ACE2 helping blood vessels relax, it helps the virus get into the host where it makes more virus instead of helping the lungs relax and do their job,” says Yu.
While the researchers are still putting the pieces together, reduced levels of ACE2 appear to enable less apelin and less protection.
However it happens, their finding of dramatic reductions in apelin in the face of ARDS, makes levels of the protective peptide a potential early biomarker for ARDS and response to treatment efforts, they say.
The new finding was their first in learning more about how CBD produces the beneficial effects they saw in their model of ARDS. Next steps include better understanding the interaction between CBD, apelin and the novel coronavirus including why apelin goes down in the face of the virus and why CBD brings it up. That includes exploring how eliminating apelin affects ARDS and if CBD produces the same lung benefit without apelin.
Likely the virus suppresses something that suppresses apelin, they say and CBD interferes. But they doubt the apelin-CBD interaction is the only way the compound, the second most prevalent found in the marijuana plant, works in this and other scenarios.
The studies were enabled by the investigators’ development of a safe, relatively inexpensive model of ARDS by giving a synthetic analog of double-stranded RNA called POLY (I:C). The novel coronavirus also has double-stranded RNA, while ours is single-stranded, so this analog produced a response similar to the virus, including the extreme lung damage that has led to the need for ventilator and other extreme support measures for patients, and is a major cause of death. Much as with the SARS-CoV-2 infection, the result is the “cytokine storm” that reflects an over-the-top immune response in the lungs, which results in an attack rather than protection.
For these studies, a control group received intranasal saline for three consecutive days while the COVID-19 model received POLY (I:C) intranasally for three days. A third group, the treatment group, received POLY ((I:C) and CBD over the same timeframe.
This time they looked and also found significantly reduced apelin levels in the mice that developed COVID-like symptoms compared to controls. Treatment with CBD normalized the immune response and apelin levels, along with oxygen levels and swelling and scarring in the lungs characteristic of the deadly ARDS.
“The apelinergic system is a very, very ubiquitous signaling system,” Yu says. While it has diverse jobs in different places, and levels may rise and fall depending on what is needed, its levels are consistently measurable in the lungs, one of the reasons it should be a good biomarker, and it’s also generally considered protective, they say.
Apelin’s important, diverse roles include helping ensure the placenta is well supplied with blood and the oxygen and nutrients it carries during a pregnancy. In fact, DCG and MCG investigators decided to look at apelin because of the work of Dr. Évila Lopes Salles, a postdoctoral fellow with Baban in the DCG Department of Oral Biology and the study’s first author, who was looking at the peptide’s significant impact in gestation and clear anti-inflammatory role, Baban says.
Synthetic agonists that increase apelin levels exist and are showing promise in the laboratory for cardiovascular disease, including slowing the growth rate of weak points in blood vessels called aneurysms. CBD appears to be a natural apelin agonist, the researchers say.
Effects of cannabis on lung function: a population-based cohort study
The effects of cannabis on lung function remain unclear and may be different from those of tobacco. We compared the associations between use of these substances and lung function in a population-based cohort (n = 1,037).
Cannabis and tobacco use were reported at ages 18, 21, 26 and 32 yrs. Spirometry, plethysmography and carbon monoxide transfer factor were measured at 32 yrs. Associations between lung function and exposure to each substance were adjusted for exposure to the other substance.
Cumulative cannabis use was associated with higher forced vital capacity, total lung capacity, functional residual capacity and residual volume. Cannabis was also associated with higher airway resistance but not with forced expiratory volume in 1 s, forced expiratory ratio or transfer factor. These findings were similar among those who did not smoke tobacco. In contrast, tobacco use was associated with lower forced expiratory volume in 1 s, lower forced expiratory ratio, lower transfer factor and higher static lung volumes, but not with airway resistance.
Cannabis appears to have different effects on lung function from those of tobacco. Cannabis use was associated with higher lung volumes, suggesting hyperinflation and increased large-airways resistance, but there was little evidence for airflow obstruction or impairment of gas transfer.
The pulmonary effects of smoking cannabis have not been extensively researched. In common with tobacco, smoking cannabis is associated with airway inflammation and symptoms of bronchitis, although the evidence that it causes airflow obstruction is not conclusive 1–5. Among the reasons for this continuing uncertainty are its illegal status, making it difficult to obtain reliable estimates of cannabis exposure, and the common practice of combining cannabis with tobacco, which makes it difficult to separate the effects of the two substances 6. Thus, although cannabis is widely used throughout the world, there is a paucity of information on its respiratory effects.
Apart from the respective psychoactive components of cannabinoids and nicotine, cannabis and tobacco smoke contain a similar mix of toxic and irritant chemicals 7. However, there are reasons to suspect that their effects on the respiratory system may not be the same. Cannabis smokers tend to smoke fewer cigarettes a day than tobacco smokers, but these tend to be packed more loosely and unfiltered. Differences in depth of inhalation, breath-hold time and leaving a shorter butt may increase the deposition of tar and carbon monoxide absorption from cannabis smoke 8–10. Several case reports of bullous lung disease in young cannabis smokers raise the possibility that cannabis (or the techniques used to smoke it) may have a greater effect on lung parenchyma than tobacco 11–13, although this association has been disputed 14. A recent report comparing smokers of cannabis and tobacco found that, although both cannabis and tobacco smokers had evidence of airflow obstruction on spirometry, cannabis was associated with more lung hyperinflation on lung volume measurement but a lower risk of emphysema on computed tomography (CT) scanning than tobacco 15. Although these findings do not support the suggestion that cannabis smokers are more susceptible to emphysema, they do indicate that cannabis and tobacco may have quite different effects on lung function.
We investigated the impact of cannabis and tobacco smoking on lung function in a population-based birth cohort followed to age 32 yrs.
Participants are members of the Dunedin Multidisciplinary Health and Development Study, a longitudinal study of the health and behaviour of a complete cohort of individuals born in Dunedin, New Zealand, in 1972 and 1973 16. A total of 1,037 individuals (52% male; 91% of eligible births) participated in the age 3 yrs assessment, forming the base sample for the study. Study members represent the full range of socioeconomic status in the general population of the South Island of New Zealand and are primarily of New Zealand/European ethnicity. The cohort has been assessed at ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26 and, most recently, at 32 yrs, when we assessed 972 participants (96% of the living cohort). The Otago Ethics Committee approved the study. Written informed consent was obtained for each assessment.
Cannabis smoking history was obtained at ages 18, 21, 26 and 32 yrs 17. At each assessment participants were asked how many times they had used marijuana in the previous year. Cumulative exposure to cannabis was calculated as the number of “joint-years” since age 17 yrs. These estimates assume that the number of times marijuana had been smoked in the previous year was representative of all years since the previous assessment. Where data were not collected at a particular assessment, the amount smoked reported at the next assessment was used to calculate cumulative exposure. 1 joint-yr is defined as the equivalent of one joint a day for 1 yr.
Cumulative tobacco exposure was calculated from the reported number of cigarettes smoked per day up to 18 yrs, 18–21 yrs, 21–26 yrs and 26–32 yrs. Where data were not collected for an assessment, the amount smoked reported at the next assessment was used to calculate cumulative exposure. One pack-year is defined as the equivalent of 20 cigarettes a day for 1 yr. Those who had smoked less than one cigarette a day for 1 yr, and fewer than 20 packets in their lifetime, were regarded as nonsmokers 18.
Spirometry has been measured at each assessment since age 9 yrs. At age 32 yrs a broad range of lung function tests, including spirometry, total lung capacity (TLC), functional residual capacity (FRC), residual volume (RV), airway resistance (Raw), specific airway conductance adjusted for thoracic gas volume (sGaw), transfer factor of the lung for carbon monoxide (TL,CO) and alveolar volume (VA) were measured using the plethysmograph and a Sensormedics Vmax 6200 module (Yorba Linda, CA, USA) 19–21. This system uses a heated wire mass flow sensor and methane dilution for measurement of alveolar volume and calculation of TL,CO. A portable spirometer (Spiropro, Sensormedics) was used to test study members (n = 27) who declined to sit in the plethysmograph or were unable to attend the research unit. Spirometry was repeated 10–15 min following inhalation of 200 μg salbutamol via a metered dose inhaler and volumatic spacer device (Allen and Hanburys, Stockley Park, UK). Study members were asked to refrain from use of their inhalers and not to smoke on the day of the assessment. All tests were reviewed by a senior technician to ensure that only acceptable and reproducible results were entered for analysis. Equipment was calibrated daily, and weekly quality control measures using biological controls were performed to ensure accuracy and precision of test equipment.
At age 32 yrs, haemoglobin was measured on a Sysmex XE2100 automated haematology analyser (Sysmex Corporation, Kobe, Japan). Exhaled carbon monoxide was measured before TL,CO measurement using a Micro CO monitor (Micromedical, Rochester, UK) and the average of two tests was recorded.
Height without shoes was measured at each age. Questions were asked about current and prior asthma and asthma symptoms using previously developed questionnaires 22. Current asthma is defined as a reported diagnosis of asthma with symptoms or medication use in the previous 12 months.
To assess whether pre-existing differences in lung function influenced the propensity to smoke, regression analyses of cumulative pack-years and joint-years to age 32 yrs were performed using spirometry at age 15 yrs (forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and FEV1/FVC) as the main predictor. These analyses adjusted for sex and height at age 15 yrs.
Initial analyses of sex–cannabis and sex–tobacco smoking interaction terms found no evidence that the effect of smoking either substance was different for males and females for any of the outcomes. The independent associations between lung function measurements at age 32 yrs and cannabis and tobacco smoking were assessed by linear regression using the measurement of lung function as the dependent variable and estimates of both cannabis and tobacco exposure as independent variables. Analyses included terms for height and sex to adjust for differences in predicted lung function, as recommended by Vollmer et al. 23 except for the FEV1/FVC ratio, which was adjusted for sex only. Analyses of TL,CO also adjusted for pre-test exhaled carbon monoxide and haemoglobin. Analyses of the association of cannabis with lung function were repeated after excluding those with any lifetime history of cigarette smoking.
To assess changes in lung function associated with tobacco and cannabis smoking, regression analyses were repeated for FEV1, FVC and the FEV1/FVC ratio using the estimates of both joint-years and pack-years as predictors with adjustment for the measurements obtained at age 15 yrs. These analyses also adjusted for sex, height at age 32 yrs, change in height between ages 15 and 32 yrs, and current asthma diagnosis.
Because pregnancy may affect lung function, pregnant females were excluded (n = 31). Visual inspection of the residuals from the regression analyses identified one clear outlier who was also excluded. Lung function measurements were approximately normally distributed, except for Raw and sGaw. Repeat analyses after log-transformations of these variables to approximate normal distributions provided similar results (not shown). Analyses were performed using Stata version 10 (StataCorp, College Station, TX, USA).
Reported cannabis and tobacco use at each age are summarised in the online supplementary material. The number of study members who reported using cannabis was higher at ages 21 and 26 yrs than at ages 18 or 32 yrs (table 1 ⇓ in the supplementary material). The number of tobacco smokers was similar at all ages, although the number of heavy smokers increased with age. Cumulative pack-years of tobacco smoking by age 32 yrs correlated with joint-years of cannabis (Spearman’s ρ = 0.49, p <0.0001) (table 1⇓ ). None of the measures of spirometric lung function (FEV1, FVC or FEV1/FVC) at age 15 yrs predicted subsequent pack-years of tobacco consumption or joint-years of cannabis use by age 32 yrs (all p-values ≥0.3).
Cumulative cannabis and tobacco use up to age 32 yrs
Mean values of lung function according to the categories of cannabis and tobacco use are shown in table 2 ⇓ in the online supplementary material. When analysed separately, cannabis and tobacco were both associated with a broad range of lung function measures (tables 3 ⇓ and 4 ⇓ in the supplementary material). However, when the effects of cannabis and tobacco were considered together (i.e. with simultaneous adjustment for exposure to the other substance), different patterns of effects were observed (table 2 ⇓ ). After adjusting for tobacco exposure, cannabis was associated with significantly higher FVC values but there was no significant association with FEV1 or FEV1/FVC ratios. In contrast, tobacco was associated with a nonsignificant trend to lower FEV1 values and significantly lower FEV1/FVC ratios, but there was no association with FVC. The findings for post-bronchodilator spirometry were similar, except that in this analysis the association between tobacco smoking and lower FEV1 values was significant (table 5 in the supplementary material). Both cannabis and tobacco were associated with higher values for TLC, FRC and RV, although the association between tobacco and TLC was of borderline statistical significance (table 2 ⇓ ). Cannabis was significantly associated with higher Raw and lower sGaw. Tobacco was not associated with differences in Raw but was associated with lower sGaw with borderline statistical significance. Cannabis use was not significantly associated with TL,CO, but because of higher values for VA, transfer factor per unit lung volume (TL,CO/VA) were lower. Tobacco was associated with lower total lung TL,CO and lower TL,CO/VA, but not with VA.
Associations of cannabis and tobacco use with lung function at age 32 yrs
Association of cannabis use with lung function at age 32 yrs amongst non-tobacco smokers
Longitudinal analyses of cannabis and tobacco exposure with spirometric lung function
Associations between cannabis exposure and lung function among non-tobacco smokers are shown in table 3 ⇑ . These show a similar pattern of findings to those shown in table 2 ⇑ . Cannabis use was associated with higher values for TLC and VA and with trends to higher values for FVC and RV. Cannabis use was not associated with FEV1, FEV1/FVC or TL,CO among these study members, but was associated with higher Raw and lower sGaw.
Associations between cumulative cannabis and tobacco smoking and spirometric lung function after adjustment for spirometry measurements at 15 yrs are shown in table 4 ⇑ . Cannabis use was significantly associated with higher values for FVC, but was not significantly associated with FEV1 or FEV1/FVC ratios. Tobacco smoking was significantly associated with lower FEV1 values and with lower FEV1/FVC ratios. The pattern of findings for cannabis was similar when tobacco smokers were excluded, except that the association between joint-years and FVC was of borderline statistical significance (table 6 in the supplementary material).
These findings indicate that cannabis is associated with changes in lung function that are independent of the effects of tobacco smoke and appear to be of a different pattern. Both substances were associated with higher values for static lung volumes, indicating a tendency toward hyperinflation and gas trapping, but although cannabis was associated with increased Raw, there was little evidence that it was associated with airflow obstruction (lower FEV1/FVC ratios) once tobacco consumption had been taken into account. Cannabis was also not associated with impairment of the TL,CO. By contrast, tobacco smoking was associated with both airflow obstruction and lower TL,CO but not with Raw.
Cannabis was consistently associated with higher lung volumes, whether measured as FVC by spirometry, static lung volumes (TLC, FRC and RV) by plethysmography or as VA by gas (methane) dilution. This consistency suggests that the findings are unlikely to be an artefact of measurement technique. Moreover, cannabis use was associated with higher values for FVC at age 32 yrs in the analyses that adjusted for FVC at age 15 yrs. It is notable that, although cannabis was not significantly associated with lower TL,CO, the higher values for VA meant that the transfer factor per unit of alveolar volume (TL,CO/VA) was lower in cannabis smokers. The clinical relevance of this is uncertain.
The pattern of lung function changes with cannabis is consistent with a recent report by Aldington et al. 15, who compared lung function tests and CT scan findings in a convenience sample of volunteers who were smokers of either cannabis, tobacco, both or neither. They found that cannabis was associated with hyperinflation on both lung function tests and CT scans but that there was little evidence of emphysema. Aldington et al. 15 also found that cannabis smokers had evidence of airflow obstruction measured by the FEV1/FVC ratio, although this was of marginal statistical significance and less obvious than in tobacco smokers. In our analysis, and in an earlier report from the Dunedin cohort (up to age 26 yrs), we also found an association between cannabis smoking and lower FEV1/FVC ratios, which was of borderline significance after adjusting for tobacco use 24. These findings are in keeping with those of a recent meta-analysis that found no consistent association between long-term cannabis use and airflow obstruction 5.
Our findings also confirm two previous reports of decreased sGaw in cannabis users and indicate that cannabis impacts on large airway function despite having little effect on the FEV1/FVC ratio 15, 25. This finding is not explained by the increase in lung volumes (and therefore the thoracic gas volume used to calculate sGaw) among cannabis smokers since cannabis was also associated with increased Raw without adjustment for lung volume. This observation is compatible with the high prevalence of bronchitic symptoms and evidence of bronchial epithelial injury among cannabis smokers 3, 4. Although increased Raw may plausibly contribute to hyperinflation, the increased Raw among cannabis users did not appear to explain the higher lung volumes: adjusting for Raw made no material difference to the association between cannabis and lung volumes (data not shown).
Considered separately, cannabis and tobacco smoking were associated with a broader range of lung function findings because most smokers used both substances (tables 3 ⇑ and 4 ⇑ in the supplementary material). One potential problem with the combined cannabis–tobacco analyses is whether the regression analyses adequately adjust for the confounding influence of tobacco smoking when assessing the associations with cannabis. The analyses were therefore repeated among those with no tobacco smoking history. Although these analyses also excluded most of the heavy users of cannabis and had smaller sample sizes, the pattern of findings was similar. Among non-tobacco smokers, cannabis was significantly associated with higher values for TLC, Raw and VA, lower values for sGaw, and with nonsignificant trends to higher values for FVC and RV. There was no significant association with the FEV1, FEV1/FVC ratio or TL,CO (table 4 ⇑ ).
Why smoking cannabis might have different effects on lung function from tobacco is unclear. We found that although both substances were associated with increased lung volumes, there was little evidence of airflow obstruction or reduced gas transfer with cannabis use. It is possible that the participants had simply not smoked enough cannabis for it to have a measurable effect on lung function, but this seems unlikely in view of the evidence for increased lung volumes and Raw. Apart from the active ingredients of cannabinoids and nicotine, the inhaled combustion products in cannabis and tobacco smoke are qualitatively similar 7, although cannabis smokers may inhale more tar per cigarette/joint 8–10. One possibility is that delta-9-tetrahydrocannibiol, which is known to act as a short-term bronchodilator 5, also has long-term biological effects. Another possibility is that differences are due to the technique of smoking cannabis. Cannabis smokers tend to inhale more deeply and hold their breath for longer than tobacco smokers 8. It is plausible that this alters the distribution of smoke throughout the lungs and thereby alters the associated physiological effects on lung function. Alternatively, it is possible that some of the findings are due to the repeated deep inhalation and breath-holding techniques themselves.
This study has a number of limitations. Cannabis use was reported for the previous year at the four assessments, rather than for all of the intervening years. Our joint-years variable assumes that the consumption of cannabis was similar for the intervening years. We do not know how much cannabis was used on each occasion or whether the cannabis joints were smoked directly or through a device such as a bong/water pipe. By comparison, tobacco smoking histories were taken for all years of the assessment period, cigarettes tend to vary less in tobacco content 15, and the practice of smoking tobacco through devices such as a bong is very unusual. Hence, the measure of cannabis exposure may be less accurate than that of tobacco, although this measurement error is unlikely to have biased the findings with respect to lung function. Errors in cannabis and tobacco consumption will also have occurred because if data were missing for an assessment, we used the amount reported at the next assessment for the calculation of joint- and pack-years. However, repeating the analysis after excluding those with missing data provided very similar findings. It is also possible that study members were less honest in reporting cannabis use than tobacco use, because it is an illegal substance. However, self-reports of cannabis use correlate well with biological markers of use 26, and our well-established record of confidentiality and nonintervention over 30 yrs of the lives of the study members tends to encourage frank reporting of these behaviours. We cannot rule out the possibility that some smokers mixed cannabis with tobacco in the same joint. Although this is not a common practice in New Zealand 15, any mixing of the two substances is most likely to have obscured the differences in the pattern of lung function changes between the two and is unlikely to explain our findings.
The study also has a number of strengths. Both cannabis and tobacco smoking were assessed on a number of occasions throughout early adult life in a population-based cohort with minimal loss to follow-up. We have a comprehensive assessment of lung function at age 32 yrs and, although plethysmography was only performed at the most recent assessment, we have measurements of spirometry pre-dating the exposure to cannabis and tobacco to investigate whether baseline lung function influenced the propensity to smoke (e.g. a “healthy smoker” effect). This analysis provided no evidence for an association between spirometry at age 15 yrs and subsequent use of tobacco or cannabis.
In conclusion, cannabis and tobacco smoking are each associated with a distinct pattern of lung function changes in young adults. Cannabis was associated with evidence of hyperinflation and increased large airway resistance, with little evidence of airflow obstruction or impairment of gas transfer, whereas tobacco was associated with airflow obstruction, gas trapping and lower transfer factors. These findings suggest that smoking cannabis and tobacco have different physiological consequences for the lungs.
This research was supported by UK Medical Research Council (London, UK) grants G0100527, G0601483, US National Institutes of Mental Health (Bethesda, MD, USA) grants MH45070 and MH49414, and the William T. Grant Foundation (New York, NY, USA). The Dunedin Multidisciplinary Health and Development Research Unit is funded by the Health Research Council of New Zealand (Auckland, New Zealand). M.R. Sears holds the AstraZeneca Chair in Respiratory Epidemiology at McMaster University (Hamilton, ON, Canada) and A. Caspi is a Royal Society-Wolfson Merit Award holder.
Statement of interest
We are grateful to the study members and their families and friends for their continued support. We also thank P.A. Silva, the study founder.
This article has supplementary material accessible from www.erj.ersjournals.com
For editorial comments see page 3.
- Received April 19, 2009.
- Accepted June 26, 2009.
- © ERS Journals Ltd
Roth MD, Arora A, Barsky SH, et al. Airway inflammation in young marijuana and tobacco smokers. Am J Respir Crit Care Med 1998 ; 157 : 928 –937.
Fligiel SE, Roth MD, Kleerup EC, et al. Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. Chest 1997 ; 112 : 319 –326.
Taylor DR, Poulton R, Moffitt TE, et al. The respiratory effects of cannabis dependence in young adults. Addiction 2000 ; 95 : 1669 –1677.
Tashkin DP, Baldwin GC, Sarafian T, et al. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 2002 ; 42 : 71S –81S.
Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007 ; 167 : 221 –228.
Hoffmann D, Brunnemann KD, Gori GB, et al. On the carcinogenicity of marijuana smoke. Recent Adv Phytochem 1975 ; 9 : 63 –81.
Wu TC, Tashkin DP, Djahed B, et al. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 1988 ; 318 : 347 –351.
Tashkin DP, Gliederer F, Rose J, et al. Tar, CO and Δ9THC delivery from the 1st and 2nd halves of a marijuana cigarette. Pharmacol Biochem Behav 1991 ; 40 : 657 –661.
Tashkin DP, Gliederer F, Rose J, et al. Effects of varying marijuana smoking profile on deposition of tar and absorption of CO and Δ-9-THC. Pharmacol Biochem Behav 1991 ; 40 : 651 –656.
Johnson MK, Smith RP, Morrison D, et al. Large lung bullae in marijuana smokers. Thorax 2000 ; 55 : 340 –342.
Beshay M, Kaiser H, Niedhart D, et al. Emphysema and secondary pneumothorax in young adults smoking cannabis. Eur J Cardiothorac Surg 2007 ; 32 : 834 –838.
Hii SW, Tam JD, Thompson BR, et al. Bullous lung disease due to marijuana. Respirology 2008 ; 13 : 122 –127.
Tan C, Hatam N, Treasure T. Bullous disease of the lung and cannabis smoking: insufficient evidence for a causative link. J R Soc Med 2006 ; 99 : 77 –80.
Aldington S, Williams M, Nowitz M, et al. The effects of cannabis on pulmonary structure, function and symptoms. Thorax 2007 ; 62 : 1058 –1063.
Hancox RJ, Poulton R, Greene JM, et al. Associations between birth weight, early childhood weight gain, and adult lung function. Thorax 2008 ; 64 : 228 –232.
Thomson WM, Poulton R, Broadbent JM, et al. Cannabis smoking and periodontal disease among young adults. JAMA 2008 ; 299 : 525 –531.
Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978 ; 118 : 1 –120.
American Thoracic Society: Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995 ; 152 : 1107 –1136.
Coates AL, Peslin R, Rodenstein D, et al. Measurement of lung volumes by plethysmography. Eur Respir J 1997 ; 10 : 1415 –1427.
American Thoracic Society: Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique–1995 update. Am J Respir Crit Care Med 1995 ; 152 : 2185 –2198.
Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003 ; 349 : 1414 –1422.
Vollmer WM, Johnson LR, McCamant LE, et al. Methodologic issues in the analysis of lung function data. J Chronic Dis 1987 ; 40 : 1013 –1023.
Taylor DR, Fergusson DM, Milne BJ, et al. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. Addiction 2002 ; 97 : 1055 –1061.
Tashkin DP, Coulson AH, Clark VA, et al. Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. Am Rev Respir Dis 1987 ; 135 : 209 –216.
Martin GW, Wilkinson DA, Kapur BM. Validation of self-reported cannabis use by urine analysis. Addict Behav 1988 ; 13 : 147 –150.